Lexington, Massachusetts-based Fractyl Laboratories Inc, a life sciences company focused on reversing the metabolic disease epidemic, has raised $55 million in Series E financing. Taiwania Capital Management Corporation led the round with participation from other investors that included Bessemer Venture Partners, General Catalyst, Domain Associates, Mithril Capital Management, Emergent Medical Partners, True Ventures, GV, Catalio Capital Management, CDIB Venture Capital Corp., and YJ Capital.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: